 | Up a level |
Journal Article
Furstenau, Moritz 
ORCID: 0000-0002-6593-0140, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael and Cramer, Paula ORCID: 0000-0003-4046-9922
(2022).
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Clin. Cancer Res., 28 (19).
S. 4203 - 4212.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 1557-3265
Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael
(2021).
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO).
Haematologica, 106 (2).
S. 543 - 555.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078